Jesus Avila

Prof. Jesus Avila

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2004 in Physiological Reviews
Verified
Journal Article
Closed access
PDF file
JAJesus Avila
Jesus Avila
JLJosé J. Lucas
José J. Lucas
MPMar Pérez
Mar Pérez
FHFélix Hernández
Félix Hernández
Avila, Jesús, José J. Lucas, Mar Pérez, and Félix Hernández. Role of Tau Protein in Both Physiological and Pathological Conditions. Physiol Rev 84: 361–384, 2004; 10.1152/physrev.00024.2003.—The morphology of a neuron is determined by its cytoskeletal scaffolding. Thus proteins that associate with the principal cytoskeletal compo-nents such as the microtubules have a strong influence on both the morphology and physiology of neurons. Tau is a microtubule-associated protein that stabilizes neuronal microtubules under normal physiological conditions. However, in certain pathological situations, tau protein may undergo modifications, mainly through phosphorylation, that can result in the generation of aberrant aggregates that are toxic to neurons. This process occurs in a number of neurological disorders collectively known as tauopathies, the most commonly recognized of which is Alzheimer's disease. The purpose of this review is to define the role of tau protein under normal physiological conditions and to highlight the role of the protein in different tauopathies.

15 January 2001 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
JLJosé J. Lucas
José J. Lucas
FHFélix Hernández
Félix Hernández
PGPilar Gómez‐Ramos
Pilar Gómez‐Ramos
MMMaría A. Morán
María A. Morán
RHRené Hen
René Hen
JAJesus Avila
Jesus Avila
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

21 May 2014 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
PDF file
MLMaria Llorens-Martín
Maria Llorens-Martín
JJJerã³Nimo Jurado
Jerã³Nimo Jurado
FHFã©Lix Hernã¡Ndez
Fã©Lix Hernã¡Ndez
JAJesus Avila
Jesus Avila
Alzheimer disease (AD) is the most common form of age-related dementia. The etiology of AD is considered to be multifactorial as only a negligible percentage of cases have a familial or genetic origin. Glycogen synthase kinase-3 (GSK-3) is regarded as a critical molecular link between the two histopathological hallmarks of the disease, namely senile plaques and neurofibrillary tangles. In this review, we summarize current data regarding the involvement of this kinase in several aspects of AD development and progression, as well as key observations highlighting GSK-3 as one of the most relevant targets for AD treatment.

1 September 2009 in Neurobiology of Disease
Verified
Journal Article
Closed access
LSL. Serenó
L. Serenó
MCM. Coma
M. Coma
MRM. Rodríguez
M. Rodríguez
PSP. Sánchez-Ferrer
P. Sánchez-Ferrer
MSM.B. Sánchez
M.B. Sánchez
TGT. Gómez-Isla
T. Gómez-Isla

24 March 2021 in Cells
Verified
Journal Article
Open access
PDF file
Carmen Laura SayasCarmen Laura Sayas
Carmen Laura Sayas
JAJesus Avila
Jesus Avila
Glycogen synthase kinase-3 (GSK-3) is a ubiquitously expressed serine/threonine kinase with a plethora of substrates. As a modulator of several cellular processes, GSK-3 has a central position in cell metabolism and signaling, with important roles both in physiological and pathological conditions. GSK-3 has been associated with a number of human disorders, such as neurodegenerative diseases including Alzheimer’s disease (AD). GSK-3 contributes to the hyperphosphorylation of tau protein, the main component of neurofibrillary tangles (NFTs), one of the hallmarks of AD. GSK-3 is further involved in the regulation of different neuronal processes that are dysregulated during AD pathogenesis, such as the generation of amyloid-β (Aβ) peptide or Aβ-induced cell death, axonal transport, cholinergic function, and adult neurogenesis or synaptic function. In this review, we will summarize recent data about GSK-3 involvement in these processes contributing to AD pathology, mostly focusing on the crucial interplay between GSK-3 and tau protein. We further discuss the current development of potential AD therapies targeting GSK-3 or GSK-3-phosphorylated tau.

27 December 2012 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
FHFélix Hernández
Félix Hernández
JLJose J. Lucas
Jose J. Lucas
JAJesus Avila
Jesus Avila
Glycogen synthase kinase 3 (GSK3) is a ubiquitously expressed serine/threonine kinase that plays a key role in the pathogenesis of Alzheimer's disease (AD). GSK3 phosphorylates tau in most serine and threonine residues hyperphosphorylated in paired h